Literature DB >> 18813155

Image-guided craniotomy for cerebral metastases: techniques and outcomes.

Tze-Ching Tan1, Peter McL Black.   

Abstract

OBJECTIVE: The purpose of the present study was to analyze the outcomes after craniotomies for brain metastases in a modern series using image-guided technologies either in the regular operating room or in the intraoperative magnetic resonance imaging unit.
METHODS: Neurosurgical outcomes were analyzed for 49 patients who underwent 55 image-guided craniotomies for excision of brain metastases during a 5-year period. Tumors were located in critical and noncritical function regions of the brain. A total of 23 craniotomies for tumors in critical brain were performed using intravenous sedation anesthesia; craniotomies for noncritical function brain regions were completed under general anesthesia. The patients were also divided into Radiation Therapy Oncology Group recursive partitioning analysis (RPA) classes on the basis of age, Karnofsky Performance Scale scores, state of primary disease, and presence or absence of extracranial metastases.
RESULTS: There was no perioperative mortality. Gross total resection, as verified by postoperative contrast-enhanced computed tomography or magnetic resonance imaging, was achieved in 96% of patients. The median anesthesia time was 4.25 hours, and the median length of hospital stay was 3 days. In 51 symptomatic cases, there was complete resolution of symptoms in 70% (n = 36), improvement in 14% (n = 7), and no change in 12% (n = 6) postoperatively. No patient who was neurologically intact preoperatively deteriorated after surgery, and 93% of patients maintained or improved their functional status. Only two patients (3.6%) with significant preoperative deficits had increased long-term deficits postoperatively. The mean follow-up was 1 year, and the local recurrence rate was 16%. The median survival of the entire group was 16.23 months (17.5 mo in RPA Class I, 22.9 mo in RPA Class II, and 9.8 mo in RPA Class III).
CONCLUSION: Gross total resection of brain metastases, including those involving critical function areas, can be safely achieved with a low morbidity rate using contemporary image-guided systems. RPA Class I and II patients with controlled primary disease benefit from aggressive treatment by surgery and radiation.

Entities:  

Year:  2007        PMID: 18813155     DOI: 10.1227/01.neu.0000279228.50826.88

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

Review 1.  The impact of cerebral metastases growth pattern on neurosurgical treatment.

Authors:  Marcel A Kamp; Philipp J Slotty; Jan F Cornelius; Hans-Jakob Steiger; Marion Rapp; Michael Sabel
Journal:  Neurosurg Rev       Date:  2016-07-09       Impact factor: 3.042

2.  Operative treatment of subcortical metastatic tumours in the central region.

Authors:  J Walter; S A Kuhn; A Waschke; R Kalff; C Ewald
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

3.  Cortical mapping and frameless stereotactic navigation in the high-field intraoperative magnetic resonance imaging suite.

Authors:  David M Weingarten; Ashok R Asthagiri; John A Butman; Susumu Sato; Edythe A Wiggs; Bonita Damaska; John D Heiss
Journal:  J Neurosurg       Date:  2009-12       Impact factor: 5.115

Review 4.  The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis.

Authors:  Rasheed Zakaria; Kumar Das; Maneesh Bhojak; Mark Radon; Carol Walker; Michael D Jenkinson
Journal:  Cancer Imaging       Date:  2014-04-22       Impact factor: 3.909

5.  Retrospective study of 229 surgically treated patients with brain metastases: Prognostic factors, outcome and comparison of recursive partitioning analysis and diagnosis-specific graded prognostic assessment.

Authors:  Mirza Pojskic; Miriam H A Bopp; Markus Schymalla; Christopher Nimsky; Barbara Carl
Journal:  Surg Neurol Int       Date:  2017-10-24

Review 6.  Companion animal models of neurological disease.

Authors:  Brittanie Partridge; John H Rossmeisl
Journal:  J Neurosci Methods       Date:  2019-11-13       Impact factor: 2.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.